相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic
Damian F. Santomauro et al.
LANCET (2021)
Desvenlafaxine in the treatment of major depression: an updated overview
Trevor R. Norman et al.
EXPERT OPINION ON PHARMACOTHERAPY (2021)
Duloxetine and pregabalin in neuropathic pain of lung cancer patients
Sule Karabulut Gul et al.
BRAIN AND BEHAVIOR (2020)
Pharmacological management of depression: Japanese expert consensus
Hitoshi Sakurai et al.
JOURNAL OF AFFECTIVE DISORDERS (2020)
A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine
Daniela Rodrigues-Amorim et al.
FRONTIERS IN PSYCHIATRY (2020)
Global Burden of Disease and the Impact of Mental and Addictive Disorders
Juergen Rehm et al.
CURRENT PSYCHIATRY REPORTS (2019)
Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy
Negin Farshchian et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder
Martin A. Katzman et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2017)
Nonpharmacologic Versus Pharmacologic Treatment of Adult Patients With Major Depressive Disorder: A Clinical Practice Guideline From the American College of Physicians
Amir Qaseem et al.
ANNALS OF INTERNAL MEDICINE (2016)
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Introduction and Methods
Raymond W. Lam et al.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2016)
Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo
Y. Gao et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2015)
Desvenlafaxine 50 and 100 mg/d Versus Placebo for the Treatment of Major Depressive Disorder: A Phase 4, Randomized Controlled Trial
Anita H. Clayton et al.
JOURNAL OF CLINICAL PSYCHIATRY (2015)
Acute and Long-term Treatment of Late-Life Major Depressive Disorder: Duloxetine Versus Placebo
Michael Robinson et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2014)
Efficacy and Safety of Desvenlafaxine 25 and 50 Mg/Day in a Randomized, Placebo-Controlled Study of Depressed Outpatients
Nakao Iwata et al.
JOURNAL OF PSYCHIATRIC PRACTICE (2013)
Symptomatic and Functional Improvement in Employed Depressed Patients A Double-Blind Clinical Trial of Desvenlafaxine Versus Placebo
Boadie W. Dunlop et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2011)
Desvenlafaxine 50 and 100 mg/d in the Treatment of Major Depressive Disorder: An 8-Week, Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial and a Post Hoc Pooled Analysis of Three Studies
Karen A. Tourian et al.
CLINICAL THERAPEUTICS (2009)
Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder
Michael R. Liebowitz et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial
Patrice Boyer et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2008)
Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine
Madhukar H. Trivedi et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2008)
Once-daily duloxetine 60 mg in the treatment of major depressive disorder: Multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil
Phil Lee et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2007)
Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study
Andrew A. Nierenberg et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Beyond remission: Rationale and design of the Prevention of Recurrent Episodes of Depression with Venlafaxine for Two years (PREVENT) study
Susan G. Kornstein
CNS SPECTRUMS (2006)
Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial
D. G. S. Perahia et al.
EUROPEAN PSYCHIATRY (2006)
Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor
Darlene C. Deecher et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Comorbid depression, chronic pain, and disability in primary care
BA Arnow et al.
PSYCHOSOMATIC MEDICINE (2006)
SNRIs: The pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants
SM Stahl et al.
CNS SPECTRUMS (2005)
Duloxetine in the treatment of depression - A double-blind-placebo-controlled comparison with paroxetine
DJ Goldstein et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2004)
Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial
MJ Detke et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2004)
Effects of duloxetine on painful physical symptoms associated with depression
DJ Goldstein et al.
PSYCHOSOMATICS (2004)
Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression
MJ Detke et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2002)
Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial
MJ Detke et al.
JOURNAL OF CLINICAL PSYCHIATRY (2002)
Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial
DJ Goldstein et al.
JOURNAL OF CLINICAL PSYCHIATRY (2002)
Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors
FP Bymaster et al.
NEUROPSYCHOPHARMACOLOGY (2001)
Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects
JE Turcotte et al.
NEUROPSYCHOPHARMACOLOGY (2001)
分享论文
